Company / Shareholders' Equity
Vera Therapeutics, Inc. Shareholders' Equity History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$604.5M
FY2025
5-year range
$69.6M / $604.5M
FY2021-FY2025
Trend
+4.7%
vs FY2024
Sector context
#80 of 213
Health Care
What the data says
At $605M, Vera Therapeutics, Inc.'s shareholders' equity ranks #80 of 213 in the Health Care sector. Shareholders' Equity has increased for 5 consecutive years, from -$89M in FY2020 to $605M in FY2025.
Based on SEC 10-K filings.
$605M in FY2025 with a 3-year CAGR of +98.8%.
Improved from $102M to $605M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +98.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#80 of 213 in Health CareTop 38% of 213This company $604.5M Sector average $2.5B
▼
-76.3% below sector average
Key checks
Key Insights
- Vera Therapeutics, Inc.'s shareholders' equity has grown for 5 consecutive years.
- 3-year CAGR of +98.8%, indicating consistent growth.
- In FY2025, shareholders' equity increased 4.7% year-over-year.
- Ranks #80 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $604.5M | +4.7% |
| FY2024 | $577.2M | +467.6% |
| FY2023 | $101.7M | +32.2% |
| FY2022 | $76.9M | +10.5% |
| FY2021 | $69.6M | +177.9% |
| FY2020 | -$89.3M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026